Skip to content

Study · Observational study · n = 55,460 · 2025

3 results

Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy - a retrospective cohort study.

Aneke-Nash C, Hung KS, Wall-Wieler E, Zheng F, Sharaiha RZ

BMJ open gastroenterology2 Apr 2025Cited by 7 (Europe PMC)

PMID40175094 (opens in a new tab)PMCIDPMC11966946 (opens in a new tab)DOI10.1136/bmjgast-2024-001704 (opens in a new tab)PepBankPUB-40175094
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In adults with obesity, gastroparesis rates were 6.5 per 1000 person-years with semaglutide, 2.1 with bupropion-naltrexone and 1.1 with sleeve gastrectomy.

    In plain wordsIn adults with obesity, gastroparesis was diagnosed at 6.5 per 1000 person-years with semaglutide, 2.1 with bupropion-naltrexone and 1.1 after sleeve gastrectomy.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGastroparesis incidence rate
    Study

    n = 55,460

    Comparator
    Bupropion-naltrexone; sleeve gastrectomy
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Gastroparesis rate
    6.5 per 1000 PY
    semaglutide
    Gastroparesis rate
    2.1 per 1000 PY
    bupropion-naltrexone
    Gastroparesis rate
    1.1 per 1000 PY
    sleeve gastrectomy

    Source sentences

    Summary
    Gastroparesis rates among those treated with semaglutide versus bupropion-naltrexone versus sleeve gastrectomy were 6.5 per 1000 person-years (PY) vs 2.1 per 1000 PY vs 1.1 per 1000 PY, respectively.
    1 context sentence
    Summary · context
    A retrospective cohort study using Merative MarketScan Research Databases of individuals with obesity who underwent treatment with semaglutide, bupropion-naltrexone or sleeve gastrectomy from 1 January 2018 to 31 December 2022.
  2. 02HumanObservational studySafety outcome

    In adults with obesity, semaglutide carried a higher adjusted risk of gastroparesis than bupropion-naltrexone (adjusted HR 3.33).

    In plain wordsIn adults with obesity, semaglutide was linked to a higher risk of gastroparesis than bupropion-naltrexone.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastroparesis risk versus bupropion-naltrexone
    Study

    n: not reported in source

    Comparator
    Bupropion-naltrexone
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Adjusted HR
    3.33 ratio
    semaglutide vs bupropion-naltrexone

    Source sentences

    Summary
    After adjusting for baseline characteristics, individuals treated with semaglutide had a higher risk of gastroparesis than those treated with bupropion-naltrexone (adjusted HR 3.33, 95% CI 2.27, 4.98) and sleeve gastrectomy (adjusted HR 6.14, 95% CI 3.94, 9.57).
    1 context sentence
    Summary · context
    A retrospective cohort study using Merative MarketScan Research Databases of individuals with obesity who underwent treatment with semaglutide, bupropion-naltrexone or sleeve gastrectomy from 1 January 2018 to 31 December 2022.
  3. 03HumanObservational studySafety outcome

    In adults with obesity, semaglutide carried a higher adjusted risk of gastroparesis than sleeve gastrectomy (adjusted HR 6.14).

    In plain wordsIn adults with obesity, semaglutide was linked to a higher risk of gastroparesis than sleeve gastrectomy.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastroparesis risk versus sleeve gastrectomy
    Study

    n: not reported in source

    Comparator
    Sleeve gastrectomy
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Adjusted HR
    6.14 ratio
    semaglutide vs sleeve gastrectomy

    Source sentences

    Summary
    After adjusting for baseline characteristics, individuals treated with semaglutide had a higher risk of gastroparesis than those treated with bupropion-naltrexone (adjusted HR 3.33, 95% CI 2.27, 4.98) and sleeve gastrectomy (adjusted HR 6.14, 95% CI 3.94, 9.57).
    1 context sentence
    Summary · context
    A retrospective cohort study using Merative MarketScan Research Databases of individuals with obesity who underwent treatment with semaglutide, bupropion-naltrexone or sleeve gastrectomy from 1 January 2018 to 31 December 2022.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.